中國同輻(01763.HK)擬斥12億元與中核資本等設合夥基金
格隆匯10月31日丨中國同輻(01763.HK)公佈，於2019年10月31日，公司董事會批准，公司將與核建基金、同心投資（擬設）訂立同創投資合夥企業（有限合夥）合夥協議，並與同創投資、中核資本、北京科創訂立同輻創新產業投資基金合夥企業（有限合夥）合夥協議。
根據同創投資合夥企業（有限合夥）合夥協議，合夥人認繳出資總額為人民幣4,250萬元，其中：核建基金認繳人民幣2,500萬元，佔比58.82%;本公司認繳人民幣750萬元，佔比17.65%；同心投資認繳人民幣1,000萬元，佔比23.53%。
根據同輻創新產業投資基金合夥企業（有限合夥）合夥協議，合夥人認繳出資總額為人民幣25億元，其中：同創投資認繳人民幣5,000萬元，佔比2%；本公司認繳人民幣12億元，佔比48%;中核資本認繳人民幣8億元，佔比32%；北京科創認繳人民幣4.5億元，佔比18%。投資範圍為同輻基金投資核素製造、放射源、核藥、醫療器械、體外診斷、醫療服務、工業輻照應用等核技術應用領域，以及其他經投資決策委員會決議審議同意的能夠與核技術應用產生協同的領域。
公司稱，公司以做大做優做強為戰略目標，堅持產業化、國際化戰略理念，努力打造國際一流的核技術應用產品和服務供應集團。為促進公司戰略落地，開拓新的經濟增長點，提升公司經濟規模和效益，中國同輻擬發起設立同輻創新產業投資基金。基金具有靈活性，圍繞中國同輻行業上下游開展投資，為戰略性、擴張性、互補拉動性收併購提供資金，中國同輻未來可以優先收購方式取得所投資項目，完善產業佈局、促進產業發展。基金將重點覆蓋：核素製造、放射源、核藥、醫療器械、體外診斷、醫療服務、工業輻照應用等核技術應用領域，實現中國同輻以投資併購為渠道的產業擴張戰略，助推中國同輻跨越式發展。
藉助中核集團內部金融板塊中核資本的資本實力和牌照優勢，引入政府引導基金，結合中國同輻產業優勢，董事會相信基金設立有利於鞏固本公司行業龍頭地位，為進一步提高市場競爭力，擴大市場佈局的良機。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
